IMSCI2.003A

App. No.

PATENT

E UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Aristo Vojdani

10/007,768

Filed November 8, 2001

SALIVA IMMUNOASSAY FOR DETECTION OF For

EXPOSURE TO INFECTIOUS AGENTS

Examiner Unknown

certify correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, PO Box 2327, Arlington VA

Group Art Unit 1645

22202, on

INFORMATION DISCLOSURE STATE FEONT CENTER 1600, 2900

United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 54 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 3 - 12 - 02

Daniel E. Altman

Registration No. 34,115

Attorney of Record

620 Newport Center Drive, 16th Floor

Newport Beach, CA 92660

(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY, DOCKET NO. IMSCI2.003A

APPLICATION NO. 10/007,768

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SPEED TO NECESSARY)

APPLICANT Aristo Vojdani

FILING DATE November 8, 2001 GROUP 1645

		TECH CENTER 1600 2000
EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	1	Schoenfeld, Y., Serer, Y., Harats, D. "Atherosclerosis as an Infectious, Inflammatory and Autoimmune Disease." <i>Trends in Immunology</i> . 22:293-295 (2001)
	2	Michalek, S.M., McGhee, J.R., Babb, J.L., "Effective Immunity to Dental Caries: Dose-Dependent Studies of Secretory Immunity by Oral Administration of Streptococcus mutans to Rats." Infect Immun 1978; 19:217-224.
	3	Husband, A.M., Gowans, "The Origin and Antigen-Dependent Distribution of IgA-Containing Cells in the Intestine." <i>J Exp. Med</i> 1978 148:1146-60
	4	Kagnoff, M.F., "Effects of Antigen-Feeding on Intestinal and Systemic Immune Responses. I. Priming of Precursor Cytotoxic T Cel by Antigen Feeding." <i>J Immunol</i> 1978; 120: 395-399.
	5	Mestecky, J., McGhee, J.R., Arnold, R.R., et al., "Selective Induction of an Immune Response in Human External Secretions by Ingestion of Bacterial Antigen." <i>J Clin Invest</i> 61: 731-737, 1978
	6	Cunningham-Rundles, C., Brandeis, W.E., et al., "Bovine Antigens and the Formation of Circulating Immune Complexes in Selective Immunoglobulin A Deficiency." <i>J Clin Invest</i> . 64:272-279, 1979
	7	Brandtzaeg, P., "Transport Models for Secretory IgA and Secretory IgM." Clin Exp. Immunol. 44:221-232, 1981.
	8	Concha, E., Subiza, J.L., et al., "Disorders of Regulatory T Cells in Patients With Selective IgA Deficiency and its Relationship to Associated Autoimmune Phenomena." Clin Exp. Immunol. 49:410-418, 1982.
	0	Bienenstock, J., Befus, A.D., "Some Thoughts on the Biologic Role of Immunoglobulin A." Gastroenterology. 84:178-185, 1983.
	10	Romero-Piffiguer, Vucovich, P.R., and Riera, C.M., "Secretory IgA and Secretory Component in Women Affected by Recidivant Vaginal Candidiasis." <i>Mycopathologia</i> 91:165-170, 1985.
	11	Stone, A.A., Cox, D.S., et al., "Secretory IgA as a Measure of Immunocompetence.", J. Human Stress. 13:136-140, 1987.
	12	Epstein, M.M., Baumgarten, A., "The Usefulness of Routine Screening For Salivary Secretory Component." <i>J Allerg Clin Immunol.</i> 88:356-360, 1991.
	13	Listgarten, M.A., "Structure of the Microbial Flora Associated With Periodontal Health and Disease in Man." <i>J. Periodontal</i> (1976) 47:1-18.
	14	Genco, R.J., "Immunoglobulins and Periodontal Disease." J. Periodontal (1970) 41:196-201.
	15	Genco, R.J. Mashimo, P.A., et al., "Antibody-Mediated Effects on the Periodontium." J. Periodontal (1974) 45:330-337.
	16	Ebersole, J.L., "Systemic Humoral Immune Responses in Periodontal Disease." Crit Rev Oral Bio Med (1990) 1:283-331.
	17	Lally, E.T., Baehni, P.C., et al., "Local Immunoglobulin Synthesis in Periodontal Disease." J. Periodont Res (1980) 15:159-164.
	18	Kiyono, H., Ogawa, T., et al., "Immune Mechanisms in Periodontitis: Total and Antigen-Specific IgG and IgA Subclass Antibody-Producing Cells at the Disease Site." <i>Protides Biological Fluids</i> (1989) 36:229-237.
	19	Tew, J.G., Marshall, D.R., et al., "Relationship Between Gingival Crevicular Fluid and Serum Antibody Titers in Young Adults and Generalized and Localized Periodontitis." <i>Infect Immun</i> (1985) 49:487-493.
	20	Schenkein, HA., "The Complement System in Periodontal Diseases." In Genco, R.J., Mergenhagen, S.E., eds. "Hosts-Parasite Interactions in Periodontal Diseases" Washington, D.C. American Society for Microbiology (1982) 299-308.
	21.	Niekrash, C.E., Patters, M.R., "Simultaneous Assessment of Complement Components C3, C4, and B and their Cleavage Products Human Gingival Fluid. II. Longitudinal Changes During Periodontal Therapy." <i>J. Periodont Res</i> (1985) 20:268-275.

H:\DOCS\CCT\CCT-2316.DOC:cb 030802

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. IMSCI2.003A APPLICATION NO. 10/007,768

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT
Aristo Vojdani

RECEIVED

(USE SEVERAL SHOTS NECESSARY)

FILING DATE November 8, 2001 GROUP MAR 2 0 2002

TECH CENTER 1600/2900

		HAR 15 DE 3	<u>U</u>
EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	22	Califano, RAD Senifferle, R.E., et al., "Antibody Reactive With <i>Porphyromonas Gingivalis</i> Serotypes K1-6 in Adult and Generalize Early-Onset Periodontitis." <i>J. Periodont</i> (1999) 70:730-735.	d
	23	Saito, S., Hayakawa, M., et al, "Opsonophagocytic Effect of Antibody Against Recombinant Conserved 40-kDa Outer Membrane Protein of <i>Porphyromonas Gingivalis</i> ." <i>J. Periodonta</i> l (1999) 70:610-617.	
	24	Rose, N.R., Herkowitz, A., et al. "Autoimmune Myocarditis: A Paradigm of Post-Infection Autoimmune Disease." <i>Immunology To</i> 9: 117-120 (1988)	oday
	25	Kroes, I., Lepp, P.W., et al., "Bacterial Diversity Within the Human Subgingival Crevice." Proc Natl Acad Sci USA. 96, 14547-149 (1999).	552
	26	Bachmaier, K., Neu, N., et al., <i>"Chlamydia</i> Infections and Heart Disease Linked Through Antigenic Mimicry." <i>Science</i> . 283, 1335 1339 (1999).	; -
	27	Ridker, P.M., Kundsin, R.B., et al., "Prospective Study of <i>Chlamydia Pneumoniae</i> IgG Seropositivity and Risks of Future Myocard Infarction." <i>Circulation</i> . 99, 1161-1164 (1999).	lial
	28	Rose, N.R., "Viral Damage or 'Molecular Mimicry'Placing the Blame in Myocarditis." Nature Medicine 6: 631-632 (2000)	
	29	Bachmaier, J., Le, J., et al., "Catching Heart Disease': Antigenic Mimicry and Bacterial Infections." Nature Medicine 6: 841-842 (2000)	
	30	Parums, D.V., Brown, D.L., et al., "Serum Antibodies to Oxidized Low-Density Lipoprotein and Ceroid in Chronic Periaortitis." Arci Pathol Lab Med 114:383-387	h
	31	Salonen, J.T., et al., Autoantibody Against Oxidised LDL and Progression of Carotid Atherosclerosis." Lancet 339:883-887 (1992)).
	32	Schoenfeld, Y., et al., "Atherosclerosis as an Infectious, Inflammatory and Autoimmune Disease." Trends in Immunology 22: 293 (2001).	-29
	33	Wick, G., Schett, G., et al., "Is Atherosclerosis an Immunologically Mediated Disease?", Immunology Today 16, 27-33 (1995).	
	34	Shoenfeld, Y., et al., "Autoantibodies Associated with Atherosclerosis." Ann Med. 32 (Suppl. 1), 37-40 (2000).	
	35	Shoenfeld, Y, et al., "Atherosclerosis and Autoimmunity." Elsevier Science (2001) 5-13	
	36	McNeil, H.P., et al., "Anti-Phospholipid Antibodies Are Directed Against a Complex Antigen that Includes a Lipid-Binding Inhibitor Coagulation: β ₂ -Glycoprotein I (Apolipoprotein H)." <i>Proc Natl Acad Sci USA</i> 87:4120-4124 (1990)	of
	37	Galli, M., et al., "Anticardiolipin Antibodies (ACA) Directed Not to Cardiolipin But to a Plasma Protein Cofactor." Lancet 335:1544 1547 (1990).	 -
	38	Kandiah, D.A., Krilis, S.A., "Immunology and Methods of Detection of Antiphospholipid Antibodies." In <i>The Antiphospholipid Syndrome</i> . R.A. Asherson, R. Cervera, J.C. Piette and Y. Shoenfeld, eds., CRC Press. Boca Raton, FL P.29-48 (1996)	
	39	Arvieux, J., et al., "Measurement of Anti-Phospholipid Antibodies by ELISA Using β ₂ -Glycoprotein I as an Antigen." <i>J. Immunol Methods</i> 143:223-229 (1991)	
	40	George, J., et al., "Adoptive Transfer of β_2 -Glycoprotein IReactive Lymphocytes Enhances Early Atherosclerosis in LDL Recept Deficient Mice." Circulation 102, 1822-1827 (2000)	lor-
	41	Sheng, Y., et al., "Anti- β_2 -Glycoprotein I Autoantibodies From Patients With the 'Antiphospholipid' Syndrome Bind to β_2 -Glycoprotein I Induces a Significant Increase in Anti- β_2 -Glycoprotein I Antibody Affinity." <i>J. of Immunology</i> 161: 2038-2043 (1998).	otei
	42	Hegde, U.M., "Platelet Antibodies in Immune Thrombocytopenia." Blood Rev 6:34-42 (1992)	

H:\DOCS\CCT\CCT-2316.DOC:cb 030702

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

c	ᇆ	FΤ	2	\triangle	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. IMSCI2.003A	APPLICATION NO. 10/007,768
	N DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Aristo Vojdani	
(USE SEVERA	AL SHEETS IF NECESSARY)	FILING DATE November 8, 2001	GROUP RECEIVED

MAR 2 0 2002 MAR 1 5 2002 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, FEOH CENTER 1600/2900 **EXAMINER** INITIAL Hasselaar, P., et al.: Crossreactivity of Antibodies Directed Against Cardiolipin, DNA, Endothelial Cells and Blood Platelets." Thromb Haemo 63: 169-173 (1990) Karpatkin, S., "Immunologic Thrombocytopenic Purpura in HIV-Seropositive Homosexuals, Narcotic Addicts and Hemophiliacs." 44 Semin Hemat Vol. 25, No. 3 (July) (1988) 219-229 Ratner, L., "Human Immunodeficiency Virus-Associated Autoimmune Thrombocytopenic Purpura: A Review." Am J Med 86: 194-198 45 (1989)46 McWilliams, N.B. Maurer, H.M., "Acute Idiopathic Thrombocytopenic Purpura in Children." Am J Hematol 7:87-96 (1979) 47 Cordiano, I., et al., "Biotin-Avidin Immobilization of Platelet Glycoproteins (BAIPG): A New Capture Assay For the Detection of Anti-Platelet Antibodies." J Immunol Methods 178 (1995) 121-130. Theofilopoulos, A.N., et al., "The Raji Cell Radioimmune Assay For Detecting Immune Complexes in Human Sera." J Clin Invest Vol. 48 57 (January) (1976) 169-182. 49 Aziz, M., et al., "Evaluation of Cell-Mediated Immunity and Circulating Immune Complexes as Prognostic Indicators in Cancer Patients." Cancer Detection and Prevention, 22(2): 87-99 (1998) Luzza, F., et al., "Evaluation of a Commercial Serological Kit for Detection of Salivary Immunoglobulin G to Helicobacter pylori: A 50 multicentre Study." Eur J of Gastroenterology & Hepatology, 2000, 12:117-1120 Tuumien, T., et al., "Development of Enzyme Immunoassays to Detect Salivary slgA to Chlamydia pneumoniae and Mycoplasma 51 pneumoniae." Scand J Clin Lab Invest 2001; 61:357-362 52 Luzza, F., et al., "Salivary Immunoglobulin G Assay To Diagnose Helicobacter pylori Infection in Children." J Clin Microbiology, Dec. 1997, Vol. 35, No. 12, pp. 3358-3360 Simor, A.E., et al., "Evaluation of Enzyme Immunoassay For Detection of Salivary Antibody to Helicobacter pylori." J Clin 53 Microbiology, Mar. 1996 Vol. 34, No. 3 p. 550-553 Luzza, F., et al., "Salivary Specific IgG is a Sensitive Indicator of the Humoral Immune Response to Helicobacter pylori. FEMS 54 Immunol Med Microbiol. 10 (1995) 281-284.

H:\DOCS\CCT\CCT-2316.DOC:cb 030802

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.